Pancreatic cancer originates from the transformed cells within the exocrine component of the same tissues found in the pancreatic region. It is among the most fatal cancers around the world. Its aggressive nature and inadequate responses to the several treatments poses as a major obstacle in the healing of such diseases. Pancreatic cancer is detected and diagnosed only when it is in its advanced stages. These stages are stage I, stage II, stage III, and stage IV of which stage I and II tumors are treatable and can be removed surgically.
The uncontrolled growth of cells in the pancreas causes pancreatic cancer and this is further classified based on whether the cancer affects the endocrine or exocrine functions of the pancreas. This growth keeps on dividing forming a mass of tissues known as tumors. The most common type of pancreatic cancer is adenocarcinomas accounting about 95% of exocrine pancreatic cancers.
Pancreatic cancer is ranked as the fourth leading cause of cancer deaths among men and women. This cancer is held responsible for causing 6% of all cancer-related deaths across the globe, and approximately 15-20% occurs in the body of the pancreas and 75% of all pancreatic carcinomas occur within the head or neck of the pancreas.
According to the leading research and advisory pharmaceutical and healthcare firms, the global pancreatic cancer drug market is estimated to reach USD 1.2 billion by 2015 and get doubled to $1.3 billion by 2022. Among all the countries in the world, the United States has marked the maximum number of pancreatic cancer cases with around 30,000 patients getting affected every year. Today, the survival rate is less than 5 years which is like a major hurdle for the expansion of this market.
To help you get a clear idea into the dynamics of this industry of pancreatic cancer, ResearchMoz brings you an entire database of well-informed market research reports by leading publishers.